RetaMaps

MD Weight Loss & MedSpa

MD Weight Loss & MedSpa · 3722 North Main Street · Baytown, TX 77521

4.8· 77 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

MD Weight Loss & MedSpa is a medical weight-loss practice and med spa in Baytown, Texas. Its website says it now offers semaglutide and tirzepatide, with ongoing medical supervision, and describes medically supervised weight loss as suited to people with a BMI of 27 or higher and weight-related health concerns. It also lists aesthetic services, and its team page describes a board-certified internal medicine physician with a specialty in obesity medicine. Weekday hours are 8:30 AM to 5:00 PM. On Google it has a 4.8-star rating across 77 reviews dating back to 2014, 7 in the past year, with the staff and results mentioned most often.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.8
Google rating · 77 reviews
7
reviews in the past year (avg ★ 5.0)
16
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2025-11-21. Read the reviews themselves on the practice's Google listing.

What patients say

This practice holds a ★4.8 Google rating across 77 reviews. 93% of the 74 reviews we analyzed are 5-star. reviewers most often mention staff & front desk (32), results (26), professionalism & expertise (17), feeling listened to (3).

5★
69
4★
2
3★
0
2★
0
1★
3

Most recent Google reviews

Jackie M.★★★★★2025-11-18

Please with staff and Dr.

Laurie C.★★★★★2025-11-18

I have lost over 60 pounds since April of this year. Great help with my weight loss journey!

Samantha G.★★★★★2025-10-09

Awesome and very friendly !

ginger o.★★★★★2025-10-03

Being coming to MD Weight Loss and Spa, for approximately 1 year and have had great success in my Weight loss journey, the staff is great, very friendly no wait time.

sylvia p.★★★★★2025-09-25

Love Dr. Nguyen and his staff! Always courteous and friendly.

Reviews and counts are from this practice's public Google Business listing and reflect their authors' opinions, not RetaMaps'. See all reviews on Google.

Clinicians

  • MD Weight Loss & MedSpa

Nearby providers in Baytown

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs